CoChat

Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis

Open access
Han, Yechen, Xie, Hongzhi, Liu, Yongtai, Gao, Peng, Yang, Xufei, Shen, Zhujun · 2019 · Cardiovascular Diabetology

The DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Metformin is the most widely prescribed drug to lower glucose and has a definitive effect on the cardiovascular system. The goal of this systematic review and meta-analysis is to assess the effects of metformin on mortality and cardiac function among patients with coronary artery disease (CAD). METHODS: Relevant studies reported before October 2018 was retrieved from databases including PubMed, EMBASE, Cochrane Library and Web of Science. Hazard ratio (HR) was calculated to evaluate the all-cause mortality, cardiovascular mortality and incidence of cardiovascular events (CV events), to figure out the level of left ventricular ejection fraction (LVEF), creatine kinase MB (CK-MB), type B natriuretic peptide (BNP) and to compare the average level of low density lipoprotein (LDL). RESULTS: In this meta-analysis were included 40 studies comprising 1,066,408 patients. The cardiovascular mortality, all-cause mortality and incidence of CV events were lowered to adjusted HR (aHR) = 0.81, aHR = 0.67 and aHR = 0. 83 respectively after the patients with CAD were given metformin. Subgroup analysis showed that metformin reduced all-cause mortality in myocardial infarction (MI) (aHR = 0.79) and heart failure (HF) patients (aHR = 0.84), the incidence of CV events in HF (aHR = 0.83) and type II diabetes mellitus (T2DM) patients (aHR = 0.83), but had no significant effect on MI (aHR = 0.87) and non-T2DM patients (aHR = 0.92). Metformin is superior to sulphonylurea (aHR = 0.81) in effects on lowering the incidence of CV events and in effects on patients who don't use medication. The CK-MB level in the metformin group was lower than that in the control group standard mean difference (SMD) = - 0.11). There was no significant evidence that metformin altered LVEF (MD = 2.91), BNP (MD = - 0.02) and LDL (MD = - 0.08). CONCLUSION: Metformin reduces cardiovascular mortality, all-cause mortality and CV events in CAD patients. For MI patients and CAD patients without T2DM, metformin has no significant effect of reducing the incidence of CV events. Metformin has a better effect of reducing the incidence of CV events than sulfonylureas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-019-0900-7

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flowchart of study selection
Fig. 1 Flowchart of study selectionCC BY · PubMed Central
Fig. 2 Forest plot of hazard ratio of cardiovascular mortality among patients with metformin therapy vs no-metformin therapy
Fig. 2 Forest plot of hazard ratio of cardiovascular mortality among patients with metformin therapy vs no-metformin therapyCC BY · PubMed Central
Fig. 3 a Forest plot of hazard ratio of all-cause mortality among patients with metformin therapy vs no-metformin therapy. b Forest plot of hazard ratio of all-cause mortality among patients with MI at baseline, metformin therapy vs no-metformin therapy. c Forest plot of hazard ratio of all-cause mortality among patients with HF at baseline, metformin therapy vs no-metformin therapy
Fig. 3 a Forest plot of hazard ratio of all-cause mortality among patients with metformin therapy vs no-metformin therapy. b Forest plot of hazard ratio of all-cause mortality among patients with MI at baseline, metformin therapy vs no-metformin therapy. c Forest plot of hazard ratio of all-cause mortality among patients with HF at baseline, metformin therapy vs no-metformin therapyCC BY · PubMed Central
Fig. 4 a Forest plot of hazard ratio of CV events among patients with metformin therapy vs no-metformin therapy. b Forest plot of hazard ratio of CV events among patients with MI at baseline, metformin therapy vs no-metformin therapy. c Forest plot of hazard ratio of CV events among patients with HF at baseline, metformin therapy vs no-metformin therapy
Fig. 4 a Forest plot of hazard ratio of CV events among patients with metformin therapy vs no-metformin therapy. b Forest plot of hazard ratio of CV events among patients with MI at baseline, metformin therapy vs no-metformin therapy. c Forest plot of hazard ratio of CV events among patients with HF at baseline, metformin therapy vs no-metformin therapyCC BY · PubMed Central
Fig. 5 a Forest plot of hazard ratio of CV events VENTS among patients with T2DM at baseline, metformin therapy vs no-metformin therapy. b Forest plot of hazard ratio of CV events among patients without T2DM at baseline, metformin therapy vs no-metformin therapy. c Forest plot of hazard ratio of CV events among patients with metformin monotherapy vs sulphonylurea monotherapy. d Forest plot of hazard ratio of CV events among patients with metformin monotherapy vs no-drug therapy
Fig. 5 a Forest plot of hazard ratio of CV events VENTS among patients with T2DM at baseline, metformin therapy vs no-metformin therapy. b Forest plot of hazard ratio of CV events among patients without T2DM at baseline, metformin therapy vs no-metformin therapy. c Forest plot of hazard ratio of CV events among patients with metformin monotherapy vs sulphonylurea monotherapy. d Forest plot of hazard ratio of CV events among patients with metformin monotherapy vs no-drug therapyCC BY · PubMed Central
Fig. 6 a Forest plot of mean difference of LVEF% among patients with metformin therapy vs no-metformin therapy. b Forest plot of mean difference of CK-MB among patients with metformin therapy vs no-metformin therapy. c Forest plot of mean difference of BNP among patients with metformin therapy vs no-metformin therapy. d Forest plot of mean difference of LDL among patients with metformin therapy vs no-metformin therapy
Fig. 6 a Forest plot of mean difference of LVEF% among patients with metformin therapy vs no-metformin therapy. b Forest plot of mean difference of CK-MB among patients with metformin therapy vs no-metformin therapy. c Forest plot of mean difference of BNP among patients with metformin therapy vs no-metformin therapy. d Forest plot of mean difference of LDL among patients with metformin therapy vs no-metformin therapyCC BY · PubMed Central
Fig. 7 a Funnel plot of hazard ratio of cardiovascular mortality among patients with metformin therapy vs no-metformin therapy. b Funnel plot of hazard ratio of all-cause mortality among patients metformin therapy vs no-metformin therapy. c Funnel plot of hazard ratio of CV events among patients with metformin therapy vs no-metformin therapy. d Funnel plot of hazard ratio of CV events among patients with T2DM at baseline, metformin therapy vs no-metformin therapy
Fig. 7 a Funnel plot of hazard ratio of cardiovascular mortality among patients with metformin therapy vs no-metformin therapy. b Funnel plot of hazard ratio of all-cause mortality among patients metformin therapy vs no-metformin therapy. c Funnel plot of hazard ratio of CV events among patients with metformin therapy vs no-metformin therapy. d Funnel plot of hazard ratio of CV events among patients with T2DM at baseline, metformin therapy vs no-metformin therapyCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 80 references

Cited by

See all 341

Metadata

Authors
Han, Y., Xie, H., Liu, Y., Gao, P., Yang, X., & Shen, Z.
Affiliations
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author
Shen, Zhujun
Venue
Cardiovascular Diabetology
Published
2019-07-30
Volume
18
Issue
1
Pages
96-96
ISSN
1475-2840 (ISSN-L)
OpenAlex
W2964576357
Cited by
337
References
81
Citations by year
2026: 17 · 2025: 35 · 2024: 56 · 2023: 52 · 2022: 73 · 2021: 52 · 2020: 48 · 2019: 4
FWCI
6.79
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Chinese Academy of Medical Sciences (CAMS) innovation fund for medical sciences (2016-I2M-1-011)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
coronary artery disease, cardiovascular mortality, all-cause mortality, cardiovascular events, myocardial infarction, heart failure, type 2 diabetes, sulfonylureas, left ventricular ejection fraction, creatine kinase-MB, natriuretic peptides, LDL cholesterol, cardiac function, antidiabetic drugs, statins, ACE inhibitors, beta-blockers, antithrombotic therapy
MeSH terms
Adult, Aged, Blood Glucose, Cause of Death, Coronary Artery Disease, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Risk Factors, Time Factors, Biomarkers, Incidence, Treatment Outcome, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. https://app.cochat.ai/papers/10.1186/s12933-019-0900-7
The paper
Han, Y., Xie, H., Liu, Y., Gao, P., Yang, X., & Shen, Z. (2019). Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-019-0900-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.